Targeted treatments for active psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with psoriatic arthritis for at least 6 months
- You currently have at least 3 tender and 3 swollen joints
- You have active psoriasis or a clear history of it
- You have tried 1 or 2 advanced medications (biologics or targeted pills) for PsA and they didn't work well or caused side effects
- You do not have HIV, active hepatitis B or C, or active tuberculosis
- You do not have another inflammatory joint condition like rheumatoid arthritis or fibromyalgia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This trial tests an oral medication called zasocitinib for adults with psoriatic arthritis who have not tried biologic medicines before. It aims to see if the drug can improve joint pain, swelling, and skin symptoms.
This trial tests a new drug called picankibart to see if it helps people with active psoriatic arthritis who haven't gotten enough relief from standard treatments like NSAIDs or non-biologic DMARDs. It may be an option if you have at least 3 tender and 3 swollen joints and active or past plaque psoriasis.
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
This study looks at how well advanced treatments work for people with psoriatic arthritis, and whether results differ for sex and gender. You may be eligible if your psoriatic arthritis is active and you are planning to start an advanced treatment for symptoms in the joints and surrounding areas.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.